Edition:
United States

AbbVie Inc (ABBV.PH)

ABBV.PH on Philadelphia Stock Exchange

61.51USD
9 Dec 2016
Change (% chg)

$0.61 (+1.00%)
Prev Close
$60.90
Open
$61.00
Day's High
$61.90
Day's Low
$61.00
Volume
27,530
Avg. Vol
41,181
52-wk High
$68.12
52-wk Low
$50.80

ABBV.PH

Chart for ABBV.PH

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and... (more)

Overall

Beta: 1.58
Market Cap(Mil.): $100,008.60
Shares Outstanding(Mil.): 1,625.10
Dividend: 0.64
Yield (%): 4.16

Financials

  ABBV.PH Industry Sector
P/E (TTM): 16.55 29.73 30.40
EPS (TTM): 3.72 -- --
ROI: 11.74 15.87 15.24
ROE: 107.29 16.99 16.58

Momenta's Humira biosimilar succeeds in key psoriasis study

U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

UPDATE 1-Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

Corporates stay strong despite market rout

LONDON, Nov 21 (IFR) - Corporate borrowers on both sides of the Atlantic shrugged off concerns about global volatility last week with pharmaceutical companies leading the charge, although they had to pay significantly higher premiums.

Nov 21 2016

BRIEF-Abbvie entered into an underwriting agreement pursuant to which Abbvie has agreed to issue notes to underwriters

* Entered into an underwriting agreement as of November 14 pursuant to which Abbvie has agreed to issue notes to underwriters

Nov 17 2016

US pharmas eye Europe's bond market amid rates volatility

LONDON, Nov 14 (IFR) - US pharmaceuticals AbbVie and Mylan have set their sights on Europe's bond market to sell debut euro bonds, taking advantage of positive sentiment for the sector after last week's unexpected Donald Trump victory in the US election.

Nov 14 2016

BRIEF-Abbvie's Humira (adalimumab) receives CHMP positive opinion to treat adolescents with Hidradenitis Suppurativa

* Abbvie's Humira receives CHMP positive opinion to treat adolescents with Hidradenitis Suppurativa, a chronic inflammatory skin disease

Nov 14 2016

AbbVie's hepatitis C treatment shows promise

Drugmaker AbbVie Inc said on Friday its experimental fixed-dose combination to treat certain hepatitis C virus patients achieved high sustained viral response (SVR) rates after eight weeks of treatment.

Nov 11 2016

AbbVie's hepatitis C treatment shows promise

Nov 11 Drugmaker AbbVie Inc said on Friday its experimental fixed-dose combination to treat certain hepatitis C virus patients achieved high sustained viral response (SVR) rates after eight weeks of treatment.

Nov 11 2016

Coherus says U.S. Patent Office denies Humira patent review

Coherus BioSciences Inc said on Monday the U.S. Patent and Trademark Office denied institution of its petition for a review of the formulation of AbbVie Inc's top-selling Humira rheumatoid arthritis treatment.

Nov 07 2016

Coherus says U.S. Patent Office denies Humira patent review

Coherus BioSciences Inc said on Monday the U.S. Patent and Trademark Office denied institution of its petition for a review of the formulation of AbbVie Inc's top-selling Humira rheumatoid arthritis treatment.

Nov 07 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $112.26 +1.27
Pfizer Inc. (PFE.N) $31.70 +0.76
Novartis AG (NOVN.S) CHF70.75 +2.25
Merck & Co., Inc. (MRK.N) $61.23 +1.11
Roche Holding Ltd. (ROG.S) CHF227.80 +7.40
Roche Holding Ltd. (RO.S) CHF231.00 +4.90
Abbott Laboratories (ABT.N) $39.20 +0.52
Eli Lilly and Co (LLY.N) $67.85 +0.66
Sanofi SA (SASY.PA) €76.33 +1.25

Earnings vs. Estimates